Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)

Inclusion Criteria: * Unresectable, locally advanced (cT4b \&/or cN2-3) HNSCC * ECOG performance status 0-1 * Age 18 or older than 18 years * Measurable disease by RECIST criteria * Having signed informed consent * ALT and AST\<2.5 times ULN * Serum albumin level ≥3.0g/dL * Serum AKP \< 2.5 times ULN * Bilirubin level \< 1.5mg/dL * Serum creatinine \<1.5 times ULN * WBC\>3000/mm3, absolute neutrophil count ≥1500/mm3, platelet\>75,000/mm3, Hb\>9g/dl Exclusion Criteria: * Previous cytotoxic chemotherapy for HNSCC * Radiotherapy for targeted lesions within six months * Previous EGFR pathway-targeting therapy * Prior surgery for cancer (excluding diagnostic biopsy within 4 weeks prior to study entry) * Distant metastatic disease * Heart failure, coronary artery disease, myocardial infarction within the last 6 months * Known allergy to any study treatment * Pregnancy or lactation period * Any investigational agent within the past 28 days * Other previous malignancy within 5 year, except adequately treated in situ cervical cancer, or non-melanoma skin cancer * Legal incapacity